Denali Therapeutics (NASDAQ:DNLI) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued a buy rating and a $31.00 target price on the stock.

A number of other equities analysts also recently commented on the company. HC Wainwright cut their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Jefferies Financial Group raised their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.42.

Denali Therapeutics Trading Down 1.4 %

NASDAQ DNLI opened at $20.58 on Tuesday. The business’s 50-day moving average price is $22.03 and its 200 day moving average price is $24.79. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The company has a market capitalization of $2.96 billion, a PE ratio of -7.46 and a beta of 1.43.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carole Ho sold 12,255 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock worth $973,442 in the last 90 days. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors have recently made changes to their positions in DNLI. FMR LLC increased its holdings in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after acquiring an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after buying an additional 1,451,770 shares during the last quarter. Wellington Management Group LLP grew its stake in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after buying an additional 903,683 shares during the last quarter. Vanguard Group Inc. grew its stake in Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after buying an additional 843,996 shares during the last quarter. Finally, Segall Bryant & Hamill LLC bought a new position in Denali Therapeutics during the 4th quarter worth $5,891,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.